Premium
An Israeli Gynecologic Oncology Group study of statin use and endometrial cancer prognosis
Author(s) -
Segev Yakir,
Gemer Ofer,
Helpman Limor,
HagYahia Nasreen,
Eitan Ram,
Raban Oded,
Vaknin Zvi,
BenArie Alon,
Amit Am,
Levy Tally,
Namazov Ahmed,
Voldarsky Michael,
Shachar Inbar Ben,
Atlas Ilan,
Bruchim Ilan,
Lavie Ofer
Publication year - 2020
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.12981
Subject(s) - medicine , endometrial cancer , hazard ratio , proportional hazards model , oncology , gynecologic oncology , retrospective cohort study , statin , cohort , cancer , survival analysis , gynecology , confidence interval
Objective To assess whether statin use by endometrial cancer patients was associated with a survival advantage. Methods A retrospective chart review study, by the Israeli Gynecologic Oncology Group, of consecutive endometrial cancer patients who underwent surgery in one of 11 medical centers between 2002 and 2014. Clinical and pathological reports, and measures of survival were compared between statin users and nonusers. Kaplan‐Meier and Cox proportional hazard models were used to assess the effect of using statins on survival measures. Results Over a mean follow‐up period of 6.2 years (range, 1–12 years) for 2017 endometrial cancer patients with complete data, 663 (32.8%) used statins prior to diagnosis and 1354 (67.1%) did not. No statistically significant differences between the groups were observed for most demographic and clinical characteristics. There was no difference between statin users and nonusers in 5‐year recurrence‐free survival (82% vs 83%; P =0.508), disease‐specific survival (86% vs 84%; P =0.549), or overall survival (77% vs 75%; P =0.901). Conclusions In this large cohort of patients with endometrial cancer, no significant associations were found between use of statins and endometrial cancer survival.